Pembrolizumab ( DrugBank: Pembrolizumab )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
25	進行性多巣性白質脳症	1
285	ファンコニ貧血	1

25. 進行性多巣性白質脳症

臨床試験数 : 26 / 薬物数 : 35 - (DrugBank : 22) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 37

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04091932 (ClinicalTrials.gov)	August 20, 2019	15/9/2019	Treatment of PD-1 Inhibitor in AIDS-associated PML	The Effect and Safety of Programmed Cell Death Protein 1 (PD-1) Inhibitor on AIDS Patients With Prog ...	Progressive Multifocal Leukoencephalopathy;AIDS	Drug: Pembrolizumab	First Affiliated Hospital of Zhejiang University	NULL	Recruiting	18 Years	65 Years	All	10	Phase 2	China

臨床試験数 : 62 / 薬物数 : 93 - (DrugBank : 30) / 標的遺伝子数 : 30 - 標的パスウェイ数 : 144

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04483544 (ClinicalTrials.gov)	December 3, 2020	20/7/2020	Pembrolizumab and Olaparib in Cervical Cancer Patients	Immunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally ...	Cervical Cancer;Cervical Carcinoma	Drug: pembrolizumab;Drug: olaparib	Baptist Health South Florida	Florida Department of Health;Merck Sharp & Dohme LLC	Recruiting	18 Years	N/A	Female	48	Phase 2	United States